MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)-- Medgenics, Inc. (NYSE MKT: MDGN and MDGN.WS and AIM: MEDG and MEDU), the developer of Biopump^TM, a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced the availability of a current prospectus following the effectiveness of its registration in the United States of common stock issuable upon the exercise of outstanding warrants to purchase 2,829,000 shares of common stock.

The warrants were originally issued in the Companys initial public offering in the United States in April 2011 and are listed on the NYSE MKT (formerly the NYSE Amex) under the symbol MDGN.WS. Each warrant is exercisable for one share of the Companys common stock, listed on the NYSE MKT under the symbol MDGN.

The shares of common stock issuable upon exercise of the warrants are being offered by the Company pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission on July 20, 2012. Electronic copies of the prospectus may be obtained at the Securities and Exchange Commissions website at http://www.sec.gov. Copies of the prospectus may also be obtained from Corporate Stock Transfer, Inc., as warrant agent, by contacting it at 3200 Cherry Creek Drive South, Suite 4300, Denver, Colorado 80209, or (303) 282-4800.

In order to exercise a warrant, the holder must deliver to Corporate Stock Transfer, Inc., 3200 Cherry Creek Drive South, Suite 4300, Denver, Colorado 80209:

• the original warrant certificate
• a completed and executed exercise form located on the reverse side of the warrant certificate and
• full payment of the exercise price, by certified check payable to Medgenics Warrant Exercise Account or by wire transfer of immediately available funds.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Medgenics (MDGN)

Medgenics is developing Biopump", a proprietary tissue-based platform technology for the sustained production and delivery of therapeutic proteins using the patient's own skin biopsy for the treatment of a range of chronic diseases including anemia, hepatitis, and hemophilia, among others.

Medgenics, Inc.
Dr. Andrew L. Pearlman, +972 4 902 8900
andrew.pearlman@medgenics.com
or
LHA
Anne Marie Fields, 212-838-3777
afields@lhai.com
@LHA_IR_PR
or
Abchurch Communications
Adam Michael/Joanne Shears/Jamie Hooper
+44 207 398 7719
jamie.hooper@abchurch-group.com
or
Nomura Code Securities (NOMAD & Joint Broker)
Jonathan Senior/Giles Balleny
+44 207 776 1200
or
SVS Securities plc (Joint Broker)
Alex Mattey/Ian Callaway
+44 207 638 5600

Source: Medgenics, Inc.

Copyright Business Wire 2012